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in the study. Of these, 33 were paid labours and 21 were unpaid ones. In the paid group, 18 participants (54.5%) were females and the mean age was 55.6 years. In the unpaid group, 16 participants (76.2%) were females and the mean age was 67.4 years. Of the 33 patients in paid labour, 4 (12.1%) had Step 2 disease, 24 (72.7%) had Step 3 disease and 5 (15.2%) had Step 4 disease. Of the 21 patients in unpaid labour, 2 (9.5%) had Step 2 disease, 18 (85.7%) had Step 3 disease, and 1 (4.8%) had Step 4 disease. The study sample was appropriate for the clinical study question since the patients received appropriate medications prior to and after the introduction of salmeterol.
Study design
The study was a single-centre, historical case series study (before-and-after study). The length of follow-up after the introduction of salmeterol was 1 year. The outcomes in the year prior to the introduction of salmeterol were also assessed. No loss to follow-up was reported.
Analysis of effectiveness
All of the patients included in the observational study were accounted for in the analysis. The primary health outcomes used were the numbers of symptom-free days (SFDs) and symptom-free nights (SFNs). A secondary outcome was the number of unscheduled visits. Data were collected retrospectively from medical records and asthma diaries. The study and comparator groups were the same patient sample following and prior to salmeterol introduction. No statistical comparison of the characteristics of the study and comparator groups was performed.
Effectiveness results
Following the introduction of salmeterol, the number of SFDs was increased by 120.7 days per year in paid patients (95% confidence interval, CI: 83.2 -158.2; p<0.001) and by 159.2 days per year in unpaid patients (95% CI: 99.4 -218.9; p<0.001).
The number of SFNs was increased by 42.5 nights per year in paid patients (95% CI: 17.5 -102.3; p<0.001) and by 84.3 nights per year in unpaid patients (95% CI: 24.2 -144.4; p<0.001).
The number of unscheduled clinic visits requiring a drip infusion of either corticosteroids or aminophylline was reduced by 6.2 days (95% CI: 2.9 -9.5; p<0.001) in paid patients.
The reduction in unscheduled clinic visits by 3.8 days in unpaid patients was not statistically significant (95% CI: -10.9 -3.3).
Clinical conclusions
The authors concluded that the improvement of clinical symptoms occurred in association with the introduction of salmeterol.
Measure of benefits used in the economic analysis
The measure of benefit used was the savings due to productivity gains. Productivity gains were valued assuming that severe, moderate and mild attacks, stridor, and absence of attacks in the asthma diary corresponded to productivity losses of 100%, 75%, 50%, 25%, and 0%, respectively. The reader is referred to the 'Indirect costs' section for further details on the method used to assess productivity gains and losses.
Direct costs
The direct costs were not included in the economic analysis.
Statistical analysis of costs
The non-parametric Wilcoxon's signed rank test was used to compare productivity losses before and after the introduction of salmeterol in the study population. This non-parametric test was used since the null hypothesis, that the distribution of productivity losses before and after the introduction of salmeterol would show equal variation, was rejected at the 5% significance level using an F-test.
Indirect Costs
The economic analysis was based on productivity costs. The quantities (productive days) and the costs were analysed separately. A societal cost boundary was adopted. Discounting was not carried out since the timeframe of the analysis was 1 year. Productivity losses were estimated via the human capital approach in the year before and the year after the introduction of salmeterol. Productivity losses were based on the proportions of asthma attacks according to severity in the clinical study, the authors' assumed productivity loss for each severity of attack, and published mean incomes.
All data were from 2002. For paid patients, loss of productivity was expressed in yen. The mean income of paid patients was calculated according to their gender and occupation, and was based on the 2002 wages of full-time and parttime employees of the manufacturing, construction and mining industries. For unpaid patients, loss of productivity was expressed in days. Then, the authors assumed that the mean income for paid patients also applied to unpaid patients.
The results for the study population were extrapolated to the wider Japanese population. This was based on 2002 data from published labour and asthma patient surveys. For example, the numbers of paid and unpaid workers in the Japanese asthmatic population, the published proportion of Step 3 and step 4 asthmatics in that population (39.4%), and the productivity gains estimated from the study population.
Currency
Japanese yen (Y).
Sensitivity analysis
A one-way sensitivity analysis was carried out to examine the generalisability of the results, by excluding data for patients with Step 2 asthma.
Estimated benefits used in the economic analysis
In paid patients, there was a saving of Y 782,810 (95% CI: 569,300 -999,300) from reduced loss of productivity in the year after the introduction of salmeterol compared with the year prior.
In unpaid patients, there was a reduction of about 61.3 days (95% CI: 41.2 -81.3) after the introduction of salmeterol compared with the year prior. This productivity gain represented a saving of Y 756,414 (CI not reported). The side effects of treatment were not considered.
Cost results
In paid patients, the total productivity loss was Y 1,744,900 in the year prior to the introduction of salmeterol and Y 962,090 in the year following its introduction.
These data were not reported for unpaid patients.
Synthesis of costs and benefits
When the results were extrapolated to the Japanese population, it was estimated that the introduction of salmeterol resulted in productivity gains of Y 105.4 billion in the paid group and Y 64.5 billion in the unpaid group. The results were not influenced by the exclusion of Step 2 patients in the sensitivity analysis.
